Evidence map›Paper›PMID 35107374›Full record

ArticleJournal of virology2022

Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.

Shoji Miki, Yohei Kawai, Kaori Nakayama-Hosoya, Ryutaro Iwabuchi, Kazutaka Terahara, Yasuko Tsunetsugu-Yokota, Michiko Koga, Tetsuro Matano, Shin Kaneko, Ai Kawana-Tachikawa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shoji MikiAIDS Research Center, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Yohei KawaiShin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Kaori Nakayama-HosoyaAIDS Research Center, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Ryutaro IwabuchiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Kazutaka TeraharaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Yasuko Tsunetsugu-YokotaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Michiko KogaDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.
Shin KanekoShin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Ai Kawana-TachikawaAIDS Research Center, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.ORCID 0000-0002-3082-5324
National Institute of Infectious Diseases · JPKyoto University · JPTokyo University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistence of HIV latently infected cells is a barrier to HIV cure. The "kick and kill" strategy for a cure includes clearance of the viral reservoir by HIV-specific cytotoxic T lymphocytes (CTLs). However, exhaustion and senescence of T cells accelerates during HIV infection, and does not fully recover, despite complete viral suppression under antiretroviral therapy. We previously established an induced pluripotent stem cell (iPSC) from a parental HIV-specific CTL clone and generated an iPSC-derived rejuvenated HIV-specific CTL clone (iPSC-CTL), which exhibited an early memory phenotype, high proliferation capacity and effector functions

Indexed as

Induced Pluripotent Stem CellsT-Lymphocytes, CytotoxicAntiviral AgentsCells, CulturedHIV InfectionsHumansVirus ReplicationAntiviral Agentsadoptive transferCTLHIVHIV cureiPS cell technology“kick and kill” strategy

Identifiers

PMID35107374
PMCPMC8941871
OpenAlexW4210353572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.